Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165,164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, Yu H, Zhang L, Li L, Li X, Wang X, Wang M, You F, Li Z, Chang Y, Zhou Z, Yan J, Li J, Wu X, Wang Y, Wang Y, Xiang S, Chen Y, Pan G, Xu H, Zhang B, Yang L. Zhang M, et al. Among authors: chen d, chen y. Clin Cancer Res. 2022 Jul 1;28(13):2830-2843. doi: 10.1158/1078-0432.CCR-21-4097. Clin Cancer Res. 2022. PMID: 35435984 Clinical Trial.
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy.
Zhang H, Chen S, Zhang Y, Tian C, Pan J, Wang Y, Bai S, Wu Q, Su M, Xie D, Fu S, Li S, Zhang J, Chen Y, Zhu S, Qian Y, Bai L. Zhang H, et al. Among authors: chen s, chen y. Cancer Immunol Res. 2023 Dec 1;11(12):1598-1610. doi: 10.1158/2326-6066.CIR-23-0448. Cancer Immunol Res. 2023. PMID: 37756568
165,164 results
You have reached the last available page of results. Please see the User Guide for more information.